2-Decenoyl carnitine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Decenoyl carnitine
• 英文别名: 3-[(E)-dec-2-enoyl]oxy-4-(trimethylazaniumyl)butanoate
• 化学式: C17H31NO4
• 分子量: 313.4
• InChiKey: MITAQTMTDSXVQD-VAWYXSNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Method for normalization in metabolomics analysis methods with endogenous reference metabolites
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2270699A1

  公开（公告）日：2011-01-05

  The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.

  本发明涉及内源参比代谢物的使用以及对哺乳动物受试者生物样本中选定目标代谢物的量和/或浓度对应的强度数据进行归一化的方法，其中所述强度数据是通过一种或多种内源参比代谢物的代谢组学分析方法获得的、包括对所述生物样本中的所述选定目标代谢物进行至少一种体外代谢组学分析方法，同时对同一样本中的一种或多种内源性参考代谢物或其衍生物进行定量分析，其中所述内源性参考代谢物是生物样本中的化合物，它们以基本恒定的水平存在于受试者体内；所述内源性参考代谢物或其衍生物的分子质量小于 1500 Da。
• Method of diagnosing organ failure
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2284540A1

  公开（公告）日：2011-02-16

  The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method, and finally, the present invention relates to a Kit for carrying out said method.

  本发明涉及一种从体外哺乳动物受试者的生物样本中预测炎症相关器官衰竭发病可能性的可靠且具有统计学意义的方法，该方法通过受试者的由多种内源性代谢物组成的定量代谢组学图谱，并将其与由多种内源性器官衰竭预测目标代谢物组成的定量参考代谢组学图谱进行比较，从而预测受试者可能或不可能发生器官衰竭。此外，本发明还涉及内源性器官衰竭预测目标代谢物在这种方法中的实用性，最后，本发明还涉及一种用于实施所述方法的试剂盒。
• Diagnosing prostate cancer relapse
  申请人：IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H.

  公开号：EP2354794A1

  公开（公告）日：2011-08-10

  The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7α-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5β,6β-Epoxycholesterol (5b,6b,EPC); 5α,6α-Epoxycholesterol (5a,6a,EPC); and 4β-Hydroxycholesterol (4BOHC); for prognosing relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.

  本发明公开了至少一种选自以下组别的物质的用途：二酰基残基总和为 C24:0 的磷脂酰胆碱（PC aa C24:0）；二酰基残基总和为 C40：3（PC ae C40:3）；二酰基残基总和为 C40:4（PC ae C40:4）的磷脂酰胆碱；酰基残基总和为 C26:0（lysoPC a C26:0）的溶血磷脂酰胆碱；酰基残基总和为 C6:0（lysoPC a C6：0）；13(S)-羟基-9Z,11E-十八碳二烯酸（13S-HODE）；12(S)-羟基-5Z,8Z,10E,14Z-二十碳四烯酸（12S-HETE）；15（S）-羟基-5Z,8Z,11Z,13E-二十碳四烯酸（15S-HETE）；白三烯 B4（LTB4）；前列腺素 E2（PGE2）；前列腺素 D2（PGD2）；7α-羟基胆固醇（7aOHC）；7-酮胆固醇（7KC）；5β,6β-环氧胆固醇（5b,6b,EPC）；5α,6α-环氧胆固醇（5a,6a,EPC）；以及 4β-羟基胆固醇（4BOHC）；用于预测 PCa 患者体液样本或组织样本中前列腺癌（PCa）复发的情况。
• Biomarkers for assessing HIV
  申请人：IDCGS clinica de Diagnosticos Medicos

  公开号：EP2927691A1

  公开（公告）日：2015-10-07

  The present invention relates to a metabolic biomarker set for assessing HIV comprising at least one acylcarnitine (AC) and at least one sphingomyelin (SM). Moreover, the present invention relates to a method for assessing HIV in a mammalian subject which comprises obtaining a biological sample, preferably blood, from the subject and measuring in the biological sample the amount of at least one acylcarnitine (AC) and at least one sphingomyelin (SM), as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy.

  本发明涉及一种用于评估艾滋病毒的代谢生物标志物组，包括至少一种酰基肉碱（AC）和至少一种鞘磷脂（SM）。此外，本发明还涉及一种用于评估哺乳动物体内艾滋病毒的方法，该方法包括从受试者体内获取生物样本（最好是血液），并测量生物样本中至少一种酰基肉碱（AC）和至少一种鞘磷脂（SM）的含量；本发明还涉及一种适用于实施该方法的试剂盒。通过采用本发明的特定生物标记物和方法，可以更正确、更可靠地评估艾滋病毒。特别是，可以高精度地筛查和诊断患者体内的艾滋病毒，并提前预测患者对抗逆转录病毒疗法的治疗反应。
• ACYLCARNITINE COMPOSITION
  申请人：Sekisui Medical Co., Ltd.

  公开号：EP3127895A1

  公开（公告）日：2017-02-08

  A problem to be solved by the present invention is to provide an acylcarnitine composition easy to handle in a solution state and having long-term storage stability. The problem is solved by an acylcarnitine composition characterized by having at least one or more acylcarnitines dissolved in an organic solvent containing an organic acid.

  本发明要解决的一个问题是提供一种在溶液状态下易于处理并具有长期储存稳定性的酰基肉碱组合物。本发明通过一种酰基肉碱组合物来解决这一问题，该组合物的特点是至少有一种或多种酰基肉碱溶解在含有有机酸的有机溶剂中。